BIOASTER and DA VOLTERRA announced the signature of a full partnership agreement to develop a new product concept in the field of anti-infection, this follows on from an initial memorandum of understanding signed in 2013.
This is a unique opportunity to push forward an exciting innovative product designed to combat antibiotic resistance by pooling the long expertise of Da Volterra in the field and the recently set-up teams of BIOASTER in Paris and Lyon. The project, entitled DACCAR, (Destroy Antibiotics in Colon to Combat Antibiotic Resistance), aims to develop an innovative product limiting the emergence of multi-resistant bacteria in patients treated with antibiotics, thus protecting the intestinal microbial flora from antibiotics side effects.
Using a DACCAR product could result in minimizing nosocomial infections burden, maintaining the effectiveness of antibiotics (noteworthy carbapenems) reducing the spread of antibiotic resistance.
More infos on BIOASTER available at http://bioaster.org/.